News coverage about ARGENX SE-ADR (NASDAQ:ARGX) has trended somewhat positive recently, according to Accern. The research firm identifies negative and positive news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. ARGENX SE-ADR earned a news sentiment score of 0.18 on Accern’s scale. Accern also assigned news stories about the company an impact score of 47.0758512704774 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

Several research firms recently commented on ARGX. Cowen and Company reaffirmed a “buy” rating on shares of ARGENX SE-ADR in a report on Thursday, August 24th. Wedbush reaffirmed an “outperform” rating on shares of ARGENX SE-ADR in a report on Monday, June 12th. Finally, JMP Securities began coverage on ARGENX SE-ADR in a report on Monday, June 12th. They issued an “outperform” rating and a $33.00 price target for the company.

ARGENX SE-ADR (NASDAQ ARGX) remained flat at $21.50 during midday trading on Friday. 1 shares of the company traded hands. ARGENX SE-ADR has a 1-year low of $17.33 and a 1-year high of $25.00. The firm’s market capitalization is $577.73 million. The stock has a 50-day moving average of $20.82 and a 200-day moving average of $20.76.

ILLEGAL ACTIVITY WARNING: This piece of content was first published by Watch List News and is the property of of Watch List News. If you are viewing this piece of content on another site, it was copied illegally and reposted in violation of US and international copyright laws. The legal version of this piece of content can be read at

ARGENX SE-ADR Company Profile

argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company’s lead clinical stage product candidates include ARGX-113, a product in Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis and immune thrombocytopenia; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of hematological cancers, such as T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome.

Receive News & Ratings for ARGENX SE-ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ARGENX SE-ADR and related companies with Analyst Ratings Network's FREE daily email newsletter.